Spots Global Cancer Trial Database for adenocarcinoma of the pancreas
Every month we try and update this database with for adenocarcinoma of the pancreas cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| The HistoSonics Edison™ System for Treatment of Pancreatic Adenocarcinoma Using Histotripsy | NCT06282809 | Pancreas Cancer Adenocarcinoma ... Pancreatic Canc... Tumor of Pancre... | HistoSonics Edi... | 18 Years - | HistoSonics, Inc. | |
| Radiation Therapy Plus Chemotherapy in Treating Patients With Pancreatic Cancer | NCT00002689 | Pancreatic Canc... | dexamethasone fluorouracil brachytherapy phosphorus P32 radiation thera... | 18 Years - | National Cancer Institute (NCI) | |
| Dose Escalation Trial of AZD1775 and Gemcitabine (+Radiation) for Unresectable Adenocarcinoma of the Pancreas | NCT02037230 | Adenocarcinoma ... | MK-1775 Gemcitabine Radiation Thera... | 18 Years - | University of Michigan Rogel Cancer Center | |
| Fluorouracil, Gemcitabine, and Radiation Therapy in Treating Patients With Cancer of the Pancreas | NCT00003216 | Pancreatic Canc... | fluorouracil gemcitabine hyd... radiation thera... | 18 Years - | Radiation Therapy Oncology Group | |
| Positron Emission Tomography Using [18F]-Labeled Substance P Antagonist Receptor Quantifier in Finding Disease in Patients With Pancreatic Cancer | NCT00547612 | Pancreatic Canc... | high performanc... pharmacological... [18F]-labeled s... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Adjuvant GVAX Vaccine Therapy in Patients With Pancreatic Cancer | NCT00389610 | Pancreatic Canc... | GVAX pancreas v... | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| BMS-247550 in Treating Patients With Advanced Pancreatic Cancer | NCT00016965 | Pancreatic Canc... | ixabepilone | 18 Years - | National Cancer Institute (NCI) | |
| Arsenic Trioxide in Treating Patients With Pancreatic Cancer That Has Not Responded to Gemcitabine | NCT00053222 | Pancreatic Canc... | arsenic trioxid... | 18 Years - | University of Chicago | |
| QUILT-2.019: A Study of AMG 655 or AMG 479 in Combination With Gemcitabine for Treatment of Metastatic Pancreatic Cancer | NCT00630552 | Adenocarcinoma ... Metastatic Panc... Pancreatic Canc... | Placebo AMG 479 AMG 655 | 18 Years - | NantCell, Inc. | |
| Gemcitabine and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer | NCT00268411 | Pancreatic Canc... | gemcitabine hyd... oxaliplatin | 18 Years - | National Cancer Institute (NCI) | |
| Nitrocamptothecin Compared With Other Chemotherapy in Treating Patients With Recurrent or Refractory Cancer of the Pancreas | NCT00005870 | Pancreatic Canc... | fluorouracil gemcitabine hyd... mitomycin C rubitecan | 18 Years - | National Cancer Institute (NCI) | |
| Vaccine Therapy in Treating Patients With Stage I or Stage II Pancreatic Cancer | NCT00003025 | Pancreatic Canc... | vitespen | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Eribulin Mesylate as Second-Line Therapy for Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer Patients | NCT00383760 | Adenocarcinoma ... Pancreatic Canc... Recurrent Pancr... Stage II Pancre... Stage III Pancr... Stage IV Pancre... | eribulin mesyla... | 18 Years - | National Cancer Institute (NCI) | |
| QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas | NCT01231347 | Adenocarcinoma ... Advanced Solid ... Cancer Cancer of Pancr... Cancer of the P... Metastases Metastatic Canc... Metastatic Panc... Pancreas Cancer Pancreatic Canc... Bone Metastases Endocrine Cance... Oncology Oncology Patien... Solid Tumors Advanced Malign... | AMG 479 Placebo AMG 479 gemcitabine | 18 Years - | NantCell, Inc. | |
| Perifosine in Treating Patients With Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer | NCT00059982 | Pancreatic Canc... | perifosine | 18 Years - | National Cancer Institute (NCI) | |
| Ganitumab in Locally Advanced Unresectable Adenocarcinoma of the Pancreas | NCT01318642 | Adenocarcinoma ... Locally Advance... Unresectable | Gemcitabine AMG 479 Placebo | 18 Years - | Amgen | |
| Preoperative Folfirinox, Radiation Therapy for Resectable Adenocarcinoma of the Pancreas | NCT01560949 | Pancreatic Canc... | Oxaliplatin Irinotecan 5-FU Gemcitabine Radiation Thera... | 18 Years - | M.D. Anderson Cancer Center | |
| Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Pancreatic Cancer | NCT00026403 | Pancreatic Canc... | cisplatin gemcitabine hyd... radiation thera... | 18 Years - 120 Years | Alliance for Clinical Trials in Oncology | |
| Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors | NCT01233505 | Adenocarcinoma ... Adenocarcinoma ... BRCA1 Mutation ... BRCA2 Mutation ... Ovarian Mucinou... Recurrent Breas... Recurrent Colon... Recurrent Gastr... Recurrent Ovari... Recurrent Ovari... Recurrent Pancr... Recurrent Recta... Stage IA Breast... Stage IB Breast... Stage II Breast... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast... Stage IV Colon ... Stage IV Gastri... Stage IV Ovaria... Stage IV Ovaria... Stage IV Pancre... Stage IV Rectal... Unspecified Adu... | veliparib capecitabine oxaliplatin pharmacological... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Phase I Study of Gemcitabine, Sorafenib and Radiotherapy in Patients With Unresectable Pancreatic Cancer | NCT00375310 | Pancreatic Canc... Adenocarcinoma ... | Gemcitabine, So... Radiotherapy | 18 Years - | Indiana University | |
| Nitrocamptothecin Compared With Other Chemotherapy in Treating Patients With Recurrent or Refractory Cancer of the Pancreas | NCT00005870 | Pancreatic Canc... | fluorouracil gemcitabine hyd... mitomycin C rubitecan | 18 Years - | National Cancer Institute (NCI) | |
| PhII Study STA-9090 as Second or Third-Line Therapy for Metastatic Pancreas Cancer | NCT01227018 | Adenocarcinoma ... Recurrent Pancr... Stage IV Pancre... | STA-9090 Radiologic imag... blood draw | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Pilot Study Using Neoadj Chemo-Rad & EGFR-tyrosine Kinase Inhibitor for Potentially Resectable Pancreatic Cancer | NCT00243854 | Pancreatic Canc... | Tarceva | 18 Years - | Indiana University | |
| Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Stage IV Pancreatic Cancer | NCT00577889 | Adenocarcinoma ... Recurrent Pancr... Stage IV Pancre... | gemcitabine hyd... tanespimycin | 18 Years - | National Cancer Institute (NCI) | |
| Chemoradiation in Locally Advanced Pancreatic Cancer | NCT00262951 | Pancreatic Canc... | recombinant int... cisplatin fluorouracil radiation thera... Resection of tu... | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| Gemcitabine With or Without CI-994 in Treating Patients With Advanced Pancreatic Cancer | NCT00004861 | Pancreatic Canc... | gemcitabine hyd... tacedinaline | 18 Years - | Pfizer | |
| Conatumumab, Gemcitabine Hydrochloride, Capecitabine, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer | NCT01017822 | Pancreatic Canc... | conatumumab capecitabine gemcitabine hyd... 3-dimensional c... | 18 Years - | Radiation Therapy Oncology Group | |
| Fluorouracil With or Without Cisplatin in Treating Patients With Advanced or Metastatic Cancer of the Pancreas | NCT00003029 | Pancreatic Canc... | cisplatin fluorouracil | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastatic Solid Tumors, Pancreatic Cancer and Biliary Cancers | NCT01497392 | Adenocarcinoma ... Stage III Pancr... Stage IV Pancre... Unspecified Adu... | dovitinib lacta... gemcitabine hyd... capecitabine laboratory biom... enzyme-linked i... pharmacological... | 18 Years - | Roswell Park Cancer Institute | |
| Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Pancreatic Cancer | NCT00026403 | Pancreatic Canc... | cisplatin gemcitabine hyd... radiation thera... | 18 Years - 120 Years | Alliance for Clinical Trials in Oncology | |
| Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Gastrointestinal Cancer | NCT00025532 | Colorectal Canc... Esophageal Canc... Gastric Cancer Pancreatic Canc... | iodine I 131 mo... | 19 Years - | University of California, San Francisco | |
| Study To Establish Maximum Tolerated Dose (MTD) of Cyberknife in Patients With Un-Resectable Pancreas Cancer (TL002) | NCT02707328 | Pancreas Cancer Pancreatic Canc... Adenocarcinoma ... Pancreas Adenoc... Pancreatic Aden... | Gemcitabine nab-paclitaxel CyberKnife | 18 Years - | The Cooper Health System | |
| Nitrocamptothecin Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer | NCT00005869 | Pancreatic Canc... | gemcitabine hyd... rubitecan | 18 Years - | National Cancer Institute (NCI) | |
| Individualized Drug Treatment for Treating Patients With Pancreatic Cancer | NCT00276744 | Pancreatic Canc... | cetuximab capecitabine docetaxel Erlotinib Gemcitabine Irinotecan mitomycin C rapamycin conventional su... | 18 Years - 120 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| EndoTAG-1 / Gemcitabine Combination Therapy to Treat Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas | NCT00377936 | Adenocarcinoma Metastasis Pancreas Neopla... | Gemcitabine alo... EndoTAG-1 and G... EndoTAG-1 and G... EndoTAG-1 and G... | 18 Years - | MediGene | |
| Efavirenz as Second-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer | NCT00964171 | Pancreatic Canc... | efavirenz quality-of-life... | 18 Years - | National Cancer Institute (NCI) | |
| Oxaliplatin, Gemcitabine, Erlotinib, and Radiation Therapy in Treating Patients With Unresectable and/or Metastatic Pancreatic Cancer or Biliary Tract Cancer | NCT00266097 | Extrahepatic Bi... Gallbladder Can... Pancreatic Canc... | erlotinib hydro... gemcitabine hyd... oxaliplatin radiation thera... gemcitabine hyd... Oxaliplatin | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Vorinostat With XRT and 5-FU for Locally Advanced Adenocarcinoma of the Pancreas | NCT00948688 | Pancreatic Canc... Adenocarcinoma ... | Radiation thera... 5-FU Vorinostat | 18 Years - | Massachusetts General Hospital | |
| Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastatic Solid Tumors, Pancreatic Cancer and Biliary Cancers | NCT01497392 | Adenocarcinoma ... Stage III Pancr... Stage IV Pancre... Unspecified Adu... | dovitinib lacta... gemcitabine hyd... capecitabine laboratory biom... enzyme-linked i... pharmacological... | 18 Years - | Roswell Park Cancer Institute | |
| Gemcitabine With or Without Tipifarnib (R115777) in Treating Patients With Advanced Pancreatic Cancer | NCT00005648 | Pancreatic Neop... | Gemcitabine wit... Gemcitabine wit... | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| Erlotinib, Gemcitabine, and Radiation Therapy in Treating Patients With Locally Advanced Unresectable Pancreatic Cancer | NCT00063947 | Adenocarcinoma ... Recurrent Pancr... Stage II Pancre... Stage III Pancr... | erlotinib hydro... gemcitabine hyd... radiation thera... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Dose Escalation Trial of AZD1775 and Gemcitabine (+Radiation) for Unresectable Adenocarcinoma of the Pancreas | NCT02037230 | Adenocarcinoma ... | MK-1775 Gemcitabine Radiation Thera... | 18 Years - | University of Michigan Rogel Cancer Center | |
| Chemotherapy, Interferon Alfa, and Radiation Therapy in Treating Patients Who Have Undergone Surgery For Pancreatic Cancer | NCT00068575 | Pancreatic Canc... | Recombinant Int... Cisplatin Fluorouracil Radiation Thera... | 18 Years - | M.D. Anderson Cancer Center | |
| ChemoRT With Adjuvant Chemo in Pancreatic Cancer (TARCEVA) | NCT00313560 | Pancreatic Canc... | erlotinib hydro... | 18 Years - 100 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Combination Chemotherapy Plus Radiation Therapy With or Without Tipifarnib in Treating Patients With Locally Advanced Pancreatic Cancer | NCT00026104 | Adenocarcinoma ... Stage II Pancre... Stage III Pancr... | gemcitabine hyd... paclitaxel tipifarnib radiation thera... | - | National Cancer Institute (NCI) | |
| Gemcitabine With or Without Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Unresectable Pancreatic Adenocarcinoma | NCT00075452 | Pancreatic Canc... | gemcitabine hyd... oxaliplatin | 18 Years - 75 Years | National Cancer Institute (NCI) | |
| Gemcitabine Pharmacokinetics After Preoperative Chemoradiation Therapy | NCT01938716 | Pancreatic Canc... | Gemcitabine | 18 Years - | M.D. Anderson Cancer Center | |
| Gemcitabine and Radiation Therapy in Treating Patients With Locally Advanced Upper Gastrointestinal Cancer | NCT00544193 | Extrahepatic Bi... Gallbladder Can... Gastric Cancer Pancreatic Canc... Small Intestine... | gemcitabine hyd... polymerase chai... immunohistochem... conventional su... intraoperative ... radiation thera... | 18 Years - 70 Years | City of Hope Medical Center | |
| Vaccine Therapy in Treating Patients With Stage I or Stage II Pancreatic Cancer | NCT00003025 | Pancreatic Canc... | vitespen | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Cisplatin, Capecitabine, Gemcitabine and Epirubicin or Docetaxel for Patients With Stage III or IV Pancreatic Cancer | NCT00966706 | Pancreatic Canc... | capecitabine cisplatin docetaxel epirubicin hydr... gemcitabine hyd... | 18 Years - 75 Years | IRCCS San Raffaele | |
| Radiation Therapy Plus Gadolinium Texaphyrin in Treating Patients With Cancer of the Pancreas That Cannot Be Removed by Surgery | NCT00003798 | Pancreatic Canc... | motexafin gadol... radiation thera... | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Pancreatic Cancer Collaborative Registry | NCT00661882 | Pancreatic Canc... | medical chart r... questionnaire a... study of socioe... biopsy | 19 Years - 100 Years | University of Nebraska | |
| Individualized Drug Treatment for Treating Patients With Pancreatic Cancer | NCT00276744 | Pancreatic Canc... | cetuximab capecitabine docetaxel Erlotinib Gemcitabine Irinotecan mitomycin C rapamycin conventional su... | 18 Years - 120 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Pioglitazone as Second-Line in Patients With Metastatic Pancreatic Cancer After Treatment With Gemcitabine | NCT00867126 | Pancreatic Canc... | pioglitazone hy... laboratory biom... questionnaire a... quality-of-life... | 18 Years - 120 Years | University of Texas Southwestern Medical Center | |
| LMB-9 Immunotoxin in Treating Patients With Advanced Pancreatic, Esophageal, Stomach, Colon, or Rectal Cancer | NCT00010270 | Colorectal Canc... Esophageal Canc... Gastric Cancer Pancreatic Canc... | LMB-9 immunotox... | 18 Years - | National Cancer Institute (NCI) | |
| Fluorouracil, External-Beam Radiation Therapy, and Gemcitabine With or Without Brachytherapy Using Phosphorus P32 in Treating Patients With Locally or Regionally Advanced Unresectable Adenocarcinoma of the Pancreas | NCT00079365 | Pancreatic Canc... | fluorouracil gemcitabine hyd... brachytherapy phosphorus P32 radiation thera... | 18 Years - | National Cancer Institute (NCI) | |
| Vaccine Therapy in Treating Patients With Cancer of the Gastrointestinal Tract | NCT00012246 | Colorectal Canc... Esophageal Canc... Extrahepatic Bi... Gallbladder Can... Gastric Cancer Pancreatic Canc... Small Intestine... | carcinoembryoni... incomplete Freu... sargramostim | 18 Years - | The University of Texas Medical Branch, Galveston | |
| Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma | NCT04543071 | Pancreatic Canc... Adenocarcinoma ... Adenocarcinoma | Motixafortide Cemiplimab Gemcitabine Nab paclitaxel | 18 Years - | Columbia University | |
| Durvalumab and "Booster" Radiation in Metastatic Adenocarcinoma of the Pancreas | NCT03490760 | Adenocarcinoma ... | Durvalumab Radiation Thera... | 18 Years - | Baptist Health South Florida | |
| Study To Establish Maximum Tolerated Dose (MTD) of Cyberknife in Patients With Un-Resectable Pancreas Cancer (TL002) | NCT02707328 | Pancreas Cancer Pancreatic Canc... Adenocarcinoma ... Pancreas Adenoc... Pancreatic Aden... | Gemcitabine nab-paclitaxel CyberKnife | 18 Years - | The Cooper Health System | |
| Docetaxel and Flavopiridol in Treating Patients With Refractory Metastatic Pancreatic Cancer | NCT00331682 | Adenocarcinoma ... Recurrent Pancr... Stage IV Pancre... | alvocidib docetaxel | 18 Years - | National Cancer Institute (NCI) | |
| Oxaliplatin, Gemcitabine, Erlotinib, and Radiation Therapy in Treating Patients With Unresectable and/or Metastatic Pancreatic Cancer or Biliary Tract Cancer | NCT00266097 | Extrahepatic Bi... Gallbladder Can... Pancreatic Canc... | erlotinib hydro... gemcitabine hyd... oxaliplatin radiation thera... gemcitabine hyd... Oxaliplatin | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Trial of Talabostat and Gemcitabine in Patients With Stage IV Adenocarcinoma of the Pancreas | NCT00116389 | Pancreatic Canc... Neoplasm Metast... Adenocarcinoma | talabostat mesy... gemcitabine | 18 Years - | Point Therapeutics | |
| Gemcitabine, Capecitabine, and Bevacizumab in Treating Patients With Pancreatic Cancer That Can Be Removed By Surgery | NCT00524069 | Pancreatic Canc... | bevacizumab capecitabine gemcitabine hyd... flow cytometry laboratory biom... adjuvant therap... computed tomogr... neoadjuvant the... | 18 Years - | Roswell Park Cancer Institute | |
| Flavopiridol Plus Radiation Therapy Followed By Gemcitabine Hydrochloride in Treating Patients With Locally Advanced, Unresectable Pancreatic Cancer | NCT00047307 | Adenocarcinoma ... Recurrent Pancr... Stage II Pancre... Stage III Pancr... Stage IV Pancre... | alvocidib gemcitabine hyd... 3-dimensional c... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas | NCT00003810 | Pancreatic Canc... | docetaxel gemcitabine hyd... | 18 Years - 120 Years | Eastern Cooperative Oncology Group | |
| Gemcitabine and CT-011 for Resected Pancreatic Cancer | NCT01313416 | Pancreatic Neop... Cancer of the P... Neoplasms Pancr... Pancreatic Canc... Pancreas Cancer | CT-011 Gemcitabine | 18 Years - | Augusta University | |
| Sorafenib and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer | NCT00095966 | Adenocarcinoma ... Recurrent Pancr... Stage II Pancre... Stage III Pancr... Stage IV Pancre... | sorafenib tosyl... gemcitabine hyd... | 18 Years - | National Cancer Institute (NCI) | |
| Gemcitabine With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer | NCT00088894 | Adenocarcinoma ... Recurrent Pancr... Stage II Pancre... Stage III Pancr... Stage IV Pancre... | gemcitabine hyd... bevacizumab placebo laboratory biom... pharmacogenomic... pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer | NCT00112658 | Pancreatic Canc... | fluorouracil gemcitabine hyd... irinotecan hydr... leucovorin calc... oxaliplatin | 18 Years - 75 Years | UNICANCER | |
| Visceral Lymphatic Mapping Using Isosulfan Blue in Patients With Cancer of the Pancreas, Colon, Stomach, Small Intestine, or Gallbladder | NCT00489515 | Colorectal Canc... Gallbladder Can... Gastric Cancer Pancreatic Canc... Small Intestine... | 18 Years - 120 Years | Wake Forest University Health Sciences | ||
| Bevacizumab and Gemcitabine Combined With Either Cetuximab or Erlotinib in Treating Patients With Advanced Pancreatic Cancer | NCT00091026 | Adenocarcinoma ... Recurrent Pancr... Stage II Pancre... Stage III Pancr... Stage IV Pancre... | cetuximab gemcitabine hyd... bevacizumab erlotinib hydro... | 18 Years - | National Cancer Institute (NCI) | |
| Fluorouracil With or Without Cisplatin in Treating Patients With Advanced or Metastatic Cancer of the Pancreas | NCT00003029 | Pancreatic Canc... | cisplatin fluorouracil | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Vaccine Therapy in Treating Patients With Advanced or Metastatic Cancer | NCT00027534 | Breast Cancer Colorectal Canc... Gallbladder Can... Gastric Cancer Head and Neck C... Liver Cancer Ovarian Cancer Pancreatic Canc... Testicular Germ... | TRICOM-CEA(6D) | 18 Years - | Duke University | |
| Fluorouracil, Gemcitabine, and Radiation Therapy in Treating Patients With Cancer of the Pancreas | NCT00003216 | Pancreatic Canc... | fluorouracil gemcitabine hyd... radiation thera... | 18 Years - | Radiation Therapy Oncology Group | |
| Vaccine Therapy in Treating Patients With Cancer of the Gastrointestinal Tract | NCT00012246 | Colorectal Canc... Esophageal Canc... Extrahepatic Bi... Gallbladder Can... Gastric Cancer Pancreatic Canc... Small Intestine... | carcinoembryoni... incomplete Freu... sargramostim | 18 Years - | The University of Texas Medical Branch, Galveston | |
| Valproic Acid/Simvastatin Plus Gemcitabine/Nab-paclitaxel Based Regimens in Untreated Metastatic Pancreatic Adenocarcinoma Patients | NCT05821556 | Adenocarcinoma ... | Valproic acid Simvastatin 20m... Gemcitabine 100... Nab paclitaxel Cisplatin Capecitabine | 18 Years - | National Cancer Institute, Naples | |
| SBRT for Close or Positive Margins After Resection of Pancreatic Adenocarcinoma | NCT01357525 | Adenocarcinoma ... | Stereotactic Bo... | 18 Years - 99 Years | University of Pittsburgh | |
| RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma | NCT00101972 | Cancer | monoclonal anti... | 18 Years - | MacroGenics | |
| Evaluation of Ocoxin-Viusid® in Advanced Pancreatic Adenocarcinoma | NCT03717298 | Adenocarcinoma ... Pancreatic Canc... Advanced Cancer Digestive Syste... Pancreatic Neop... Endocrine Gland... Digestive Syste... Endocrine Syste... Pancreatic Dise... | Ocoxin-Viusid® | 18 Years - | Catalysis SL |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
